Introduction {#section5-2042098619843365}
============

Older adults represent a growing proportion of the population in most industrialized countries and suffer frequently from multimorbidity and resulting polypharmacy.^[@bibr1-2042098619843365],[@bibr2-2042098619843365]^ Based on physiological changes occurring with advancing age, many drugs lead to more side effects in the older population when compared with younger adults,^[@bibr3-2042098619843365],[@bibr4-2042098619843365]^ a problem which increases with the number of drugs prescribed. Polypharmacy is frequently and conveniently defined as the intake of five or more drugs per day on a regular basis;^[@bibr5-2042098619843365]^ however, the uncontrolled use of many drugs without appropriate monitoring may also be understood as polypharmacy.^[@bibr6-2042098619843365]^ Polypharmacy has been shown to be associated with drug--drug interactions (DDIs), a risk for potentially inappropriate medications (PIMs), adverse drug reactions (ADRs), drug omissions and finally increased morbidity, particularly falls, and mortality.^[@bibr7-2042098619843365],[@bibr8-2042098619843365]^

Different tools and interventions have been developed and tested to optimize polypharmacy in diverse settings.^[@bibr9-2042098619843365]^ Prospective studies were performed in the community-dwelling elderly,^[@bibr10-2042098619843365]^ in nursing homes^[@bibr11-2042098619843365]^ as well as in the hospital setting.^[@bibr9-2042098619843365]^ Most interventions included training for doctors, involvement of pharmacists and medication reviews, as well as special education for nurses, and frequently applied a team-based approach.^[@bibr9-2042098619843365]^ Many interventions focused on defined drug classes (e.g. psychotropic drugs); others targeted all prescriptions and over-the-counter drugs. The primary objective was, in many studies, the number of drugs. Very frequently, measures of 'medication quality' or appropriateness were documented applying validated instruments such as the medication appropriateness index (MAI).^[@bibr12-2042098619843365],[@bibr13-2042098619843365]^ A few studies investigated the effect of their intervention on outcomes such as hospitalization or mortality.^[@bibr9-2042098619843365],[@bibr12-2042098619843365]^ As a general trend, focused interventions (i.e. on psychotropic drugs) were more successful than broader approaches.^[@bibr11-2042098619843365]^ On the contrary, using well-controlled measures, overall medication quality can be improved substantially.^[@bibr12-2042098619843365]^

Depending on the healthcare system, different approaches may be effective and for Germany, a hospital-based intervention may have a good chance for a successful intervention. A minimum of 14 days' duration of hospital stay in a specialized geriatric department is sufficiently long to assess the physical and psychosocial condition of a patient, allowing for medication changes and deprescribing with adequate monitoring.

The aim of our study was to reduce drug-related problems (DRPs) in geriatric inpatients by a structured pharmacist's intervention and to measure the acceptance rate of the pharmacist's suggestions.

Methods {#section6-2042098619843365}
=======

Study design and setting {#section7-2042098619843365}
------------------------

This study followed an open, prospective, quasi-randomized design including an intervention and a control group and was conducted in a geriatric department (56 beds) in a teaching hospital in Germany between January and December 2015. The study protocol was approved by the responsible ethics committee of the University of Witten/Herdecke, Germany, registered under number DRKS00014560 and can be retrieved on the World Health Organization (WHO) International Clinical Trials Registry Platform.^[@bibr14-2042098619843365]^

Patients {#section8-2042098619843365}
--------

Patients of all sexes were included with a minimum age of 70 years, regular intake of at least five drugs daily after written informed consent had been obtained. Patients with an estimated life expectancy of less than 1 week, cognitive impairment or previous participation in this study during the last 3 months in the same hospital were not included. However, rehospitalized patients after more than 3 months could be included again and were counted as a new case.

The geriatric department consists of two wards (26--30 beds) and all patients are admitted to one of them, depending on the availability of a bed. This procedure was unrelated to the study and was organized by administrative hospital staff without any knowledge of the study. Patients on ward A were defined as the intervention group, whereas patients on ward B served as the control group (see [Figure 1](#fig1-2042098619843365){ref-type="fig"}). Physicians and nurses of both wards were informed about the study, but no formal training was given.

![Study design and patient enrolment.](10.1177_2042098619843365-fig1){#fig1-2042098619843365}

Study procedures {#section9-2042098619843365}
----------------

After admission to the respective wards, all patients were informed about the study by the pharmacist and inclusion/exclusion criteria were verified. After oral and written information was given, written informed consent was obtained from all study participants.

Baseline data such as age, sex, body size and weight, drugs (coded using the Anatomical Therapeutic Chemical Classification System code^[@bibr15-2042098619843365]^) and allergies, as well as relevant laboratory data were entered pseudonymized into an Access (Microsoft® Access 2016, Microsoft Germany GmbH) database. Glomerular filtration rate was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)^[@bibr16-2042098619843365]^ and Cockroft--Gault formulae.^[@bibr17-2042098619843365]^ Results of several routine geriatric tests were documented: the Barthel Index^[@bibr18-2042098619843365]^ of activities of daily living (IADL),^[@bibr19-2042098619843365]^ the timed up-and-go test,^[@bibr20-2042098619843365]^ the Tinetti test,^[@bibr21-2042098619843365]^ the clock test^[@bibr22-2042098619843365]^ and the Geriatric Depression Scale (GDS-15).^[@bibr23-2042098619843365]^

Medication assessment {#section10-2042098619843365}
---------------------

Medication of all patients in the intervention and control groups was assessed by the pharmacist at admission and discharge. In accordance with the Descriptive Elements of Pharmacist Interventions Characterization Tool (DEPICT) statement,^[@bibr24-2042098619843365]^ medication was reviewed and documented using the hospital chart and by personal interview (see [Table 1](#table1-2042098619843365){ref-type="table"}). Results of the medication analysis were documented in the Access database.

###### 

Criteria for medication assessment.

![](10.1177_2042098619843365-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                       Criterion                                            Example                                                                                                                                      Reference
  ---------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Potentially inadequate medication for older adults   PRISCUS list                                         Anticholinergic drugs, e.g. amitriptyline, oxybutynine                                                                                       Holt et al.^[@bibr25-2042098619843365]^

  Renal dosing                                         SPC                                                  Duloxetine:\                                                                                                                                 [www.fachinfo.de](https://www.fachinfo.de) ^[@bibr26-2042098619843365],[@bibr27-2042098619843365]^\
                                                                                                            GFR 30--80 ml/min: no dosage adjustment\                                                                                                     
                                                                                                            GFR \< 30ml/min: contraindicated                                                                                                             

  No indication                                        SPC and statement of the physician (off-label use)   No indication if there was no documentation of symptoms of angina pectoris                                                                   [www.fachinfo.de](https://www.fachinfo.de) ^[@bibr27-2042098619843365],[@bibr28-2042098619843365]^\

  Drug--drug interaction                               ABDA database                                        Rivaroxaban and enoxaparin: increased risk for bleeding                                                                                      ABDA database^[@bibr28-2042098619843365]^

  Adverse drug effect                                  Either detected by physician or by pharmacist        Patient with hip fracture (reason for admission) says that she often needs to go to the toilet at night: she receives diuretics at bedtime   ABDA database^[@bibr28-2042098619843365]^\
                                                                                                                                                                                                                                                         [www.fachinfo.de](https://www.fachinfo.de)^[@bibr27-2042098619843365]^

  Medication appropriateness index (MAI)               MAI                                                  MAI modification for geriatric patients in nursing homes and geriatric inpatients (Joks^[@bibr29-2042098619843365]^)                         MAI,^[@bibr13-2042098619843365]^ MAI modification after Joks^[@bibr29-2042098619843365]^

  Further information about application of the drug    SPC                                                  Patient did not use his medication correctly (e.g. inhalation of COPD drugs)                                                                 [www.fachinfo.de](https://www.fachinfo.de) ^[@bibr27-2042098619843365]^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ABDA, Federal Union of German Associations of Pharmacists; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; PRISCUS, ; SPC, summary of product characteristics.

Detection and classification of adverse drug reactions {#section11-2042098619843365}
------------------------------------------------------

At admission, all patients were screened by the responsible physician and the pharmacist for ADRs, where all symptoms described by the patient, diagnoses at admission and pathological laboratory parameters where checked. At discharge, those ADRs still described by the patient, mentioned in the discharge report and detectable in the laboratory parameters were analysed.

All ADRs were coded according to the WHO System Organ Classification on the fifth level.^[@bibr30-2042098619843365]^ Causality assessment was performed using the Naranjo algorithm.^[@bibr31-2042098619843365]^ Severity of ADRs were classified using the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) grading system.^[@bibr32-2042098619843365]^ Preventability of ADR was assessed applying the algorithm developed by Schumock and Thornton.^[@bibr33-2042098619843365]^

Intervention {#section12-2042098619843365}
------------

In both groups, medication analyses were performed ([Table 1](#table1-2042098619843365){ref-type="table"}). Recommendations wereprepared for the treating physicians of the intervention-group patients only. These recommendations were classified using the 'pharmacotherapy problem categories' according to Hoth et al.^[@bibr34-2042098619843365]^ with low, medium or high priority. This classification system is more detailed than our primary outcome criteria 'drug-related problems' and includes, for example, compliance issues and problems with the route of administration. A meeting with the physician was arranged by the pharmacist and all issues were discussed. Only in 20 cases, a face-to-face meeting was not feasible and a printout of the recommendations was placed into the patients' charts, where it was found by the visiting physician. After discussion with the physician, the recommendations were accepted, modified or rejected. Discharge reports of all study patients were screened by the pharmcist and again, a medication assessment was performed.

Outcomes {#section13-2042098619843365}
--------

Primary outcome parameter of the study was the percentage of patients with at least one DRP detected in the medication assessment. The following items were counted as DRPs and contributed to the combined primary outcome:

1.  presence of at least one drug prescribed without indication,

2.  presence of an ADR,

3.  DDI with a severity grade of at least 'concomitant use not recommended' as listed in the DDI database applied,^[@bibr28-2042098619843365]^

4.  presence of a PIM according to the German PRISCUS list.^[@bibr25-2042098619843365]^

Secondary outcome variable was the MAI, slightly adapted to the German healthcare system.^[@bibr13-2042098619843365],[@bibr29-2042098619843365]^ This adaptation excludes price issues since (a) drug prices in German hospitals are lower than in ambulatory care, and (b) drugs available in the hospital are listed on the drug formulary, where cost issues have already been considered. In addition, the question for 'missing indication' receives a lower weighting, since information available from ambulatory care is frequently incomplete and comorbidities may exist without clear information in the documentation. We consider this question as highly relevant, but in many cases, it is too difficult for the pharmacist to obtain all information required to answer this question with a high level of certainty.

Statistical analyses {#section14-2042098619843365}
--------------------

All data were documented into an Access database. For the sample size determination, the prevalence of a DRP was estimated with 50%, as described in the literature.^[@bibr35-2042098619843365][@bibr36-2042098619843365][@bibr37-2042098619843365][@bibr38-2042098619843365]--[@bibr39-2042098619843365]^ After the pharmaceutical intervention, prevalence of DRPs should be reduced to 20%. However, during routine clinical practice, optimization of medication was expected in the DRP prevalence range of 30%, at discharge. Based on these assumptions and using McNemar's test for comparison between groups, this 10% difference could be detected with a sample size of 170 patients per group with a power of 85% and a significance level of α = 0.05. To compensate for dropouts, we planned to include 200 patients per group.

Statistical analyses were performed using a full analysis set and applying a matched-pairs design. For the latter, all patients from the control and intervention groups who finished the study according to protocol were matched to achieve homogenous groups. Matching criteria were as follows: same sex, age ± 5 years and hospitalization during the same month.

To compare frequency distributions between two independent groups (full analysis set) two-sided Fisher's exact test was applied for categorical data; for continuous variables, the Wilcoxon--Mann--Whitney test. In order to compare frequency distributions for the matched-pairs analysis, McNemar's two-sided test was used.

A multivariate logistic-regression analysis was performed to assess the association between age, sex, estimated glomerular filtration rate (eGFR) and GDS (in categorial form with ⩽5 and \>5) as independent variables and (a) the presence of an ADR at admission, and (b) the presence of a DRP at admission as dependent variables. Nagelkerke's *R*^2^ has been chosen to describe the quality of the model.^[@bibr40-2042098619843365]^

Medication was analysed descriptively between admission and discharge, as well as the percentage of acceptance and implementation of pharmacist's recommendations.

All statistical analyses were performed using SPSS® version 23 (IBM®, Ehningen, Germany). Descriptive analyses were performed with Microsoft® Excel 2016 and Microsoft® Access 2016.

Results {#section15-2042098619843365}
=======

Over the 12-month study period, 411 patients were recruited ([Figure 1](#fig1-2042098619843365){ref-type="fig"}). In the following, data of the full analysis set are presented. Matching resulted in 188 pairs (65% female pairs) with comparable baseline values for age (intervention *versus* controls: females 82.7 ± 6.2 years *versus* 81.4 ± 5.9 years; males 81.6 ± 5.9 years *versus* 80.9 ± 6.3 years) and GFR {intervention *versus* controls: 54.6 ml/min/1.73 m² \[standard deviation (SD) 21.855; range 5--106 ml/min/1.73 m²\]; 60.4 ml/min/1.73 m² (SD 21.977; range 2--118 ml/min/1.73 m²)}. Supporting data of the matched-pairs analysis are presented in the additional online version ([online Table 5](https://journals.sagepub.com/doi/suppl/10.1177/2042098619843365)).

Patients {#section16-2042098619843365}
--------

Population baseline data are depicted in [Table 2](#table2-2042098619843365){ref-type="table"}. More than half (64%) of the study population was female and median age was 82 years (mean value ± SD: 81.91 ± 6.10; range 70--103 years). The higher percentage of female participants is in concordance with the prevalence of female patients on geriatric wards being 65%. Patients in the intervention group were slightly older and had a significantly lower eGFR. The median length of stay was 19 days (19.26 ± 7.69; 1--49 days). Out of the control group, six patients died during hospital stay and eight patients from the intervention group. Geriatric assessment variables are presented in [Table 3](#table3-2042098619843365){ref-type="table"} and are comparable between groups. As expected after a geriatric hospitalization, the Barthel IADL improved markedly.

###### 

Demographic data of study participants (full analysis set).

![](10.1177_2042098619843365-table2)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                  Control group (*n* = 202)                                      Intervention group (*n* = 209)                                 Difference between groups (*p* value)
  ------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------
  Age, years, mean                                                                81.3 (SD 5.95; range: 70--96)                                  82.5 (SD 6.18; range: 70--103)                                 *p* = 0.036

  Female %                                                                        61.9                                                           66.0                                                           *p* = 0.412

  Body weight, kg^[\*](#table-fn2-2042098619843365){ref-type="table-fn"}^, mean   75.2 (SD 19.476; range: 39--170)                               75.9 (SD 16.895; range: 39--138)                               *p* = 0.797

  Duration of hospital stay, days, mean                                           19.47 (SD 7.33; range 3--48)                                   19.05 (SD 8.03; range 1--49)                                   *p* = 0.584

  eGFR^[\*\*](#table-fn3-2042098619843365){ref-type="table-fn"}^\                 60.4 ml/min/1.73 m² (SD 21.977; range 2--118 ml/min/1.73 m²)   54.6 ml/min/1.73 m² (SD 21.855; range 5--106 ml/min/1.73 m²)   *p* = 0.008
  (ml/min/1,73m²), mean                                                                                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Body weight available for *n* = 114 patients in the control group, *n* = 120 patients in the intervention group.

eGFR available for *n* = 202 patients in the control group, *n* = 207 patients in the intervention group.

eGFR, estimated glomerular filtration rate; SD, standard deviation.

###### 

Clinical geriatric characteristics of the study population (full analysis set population).

![](10.1177_2042098619843365-table3)

                                                                                     Admission                                    Discharge                                                                                                                                       
  ---------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------- -------------- ----------------------------------------- ------------------------------------------ --------------
  Barthel Index (0--100)^[\*](#table-fn5-2042098619843365){ref-type="table-fn"}^     42.75 (SD 22.48; range 0--100) (*n* = 191)   39.13 (SD 20.04; range 0--100; *n* = 189)   *p* = 0.0984   67.71 (SD 25.32; 0--100; *n* = 176)       61.94 (SD 22.16; 5--100; *n* = 165)        *p* = 0.001
  IADL^[\*\*](#table-fn6-2042098619843365){ref-type="table-fn"}^                     3.78 (SD 2.53; range 0--8; *n* = 181)        3.65 (SD 2.53; range 0--8; *n* = 165)       *p* = 0.650    --                                        --                                         --
  Timed up-and-go test^[\*\*\*](#table-fn7-2042098619843365){ref-type="table-fn"}^   21.03 (SD 7.12; range 10--50; *n* = 93)      27.28 (SD 11.06; range 9--65; *n* = 86)     *p* \< 0.001   20.9 (SD 10.67; range 7--80; *n* = 114)   26.17 (SD 10.68; range 9--65; *n* = 113)   *p* \< 0.001
  Tinetti test^[\$](#table-fn8-2042098619843365){ref-type="table-fn"}^               12.40 (SD 8.39; range 0--27; *n* = 184)      9.29 (SD 6.95; range 0--27; *n* = 178)      *p* \< 0.001   16.73 (SD 7.17; range 0--27; *n* = 160)   14.40 (SD 6.41; range 0--27; *n* = 146)    *p* \< 0.001
  Clock completion test^[§](#table-fn9-2042098619843365){ref-type="table-fn"}^       3.08 (SD 1.49; range 1--6; *n* = 156)        3.30 (SD 1.28; range 1--6; *n* = 132)       *p* = 0.237    --                                        --                                         --
  GDS^[§§](#table-fn10-2042098619843365){ref-type="table-fn"}^                       4.87 (SD 3.39; range 0--14; *n* = 168)       4.41 (SD 2.95; range 0--13; *n* = 147)      *p* = 0.285    5.20 (SD 3.54; range 0--15; *n* = 91)     3.63 (SD 2.49; range 0--12; *n* = 97)      *p* = 0.003

Care dependency increases with falling Barthel Index.

IADL: 0: absolutely dependent; 8: independent.

Up-and-go test time (s): \<10 s: normal mobility; \<20 s: slightly limited mobility; \<30 s: limited mobility; \>30 s: definitive limited mobility.

Tinetti test: \>20 points: normal mobility; 15--20 points: slightly limited mobility; 10--14 points: limited mobility; \<10 points: definitive limited mobility.

Clock completion test scale, 1--6: low number indicates better cognitive skills.

GDS 0--15: 0--5: normal; \>5: depression possible.

GDS, Geriatric Depression Scale; IADL, index of activities of daily living; SD, standard deviation.

Medication and drug-related problems {#section17-2042098619843365}
------------------------------------

Patients in the intervention group received 10.85 ± 3.54 (median 10, range 5--24) drugs at admission, whereas patients in the control group received 10.26 ± 3.29 (median 10, range 5--24) drugs. At discharge, patients in the intervention group were prescribed 9.39 ± 2.93 (median 9, range 3--19) drugs, whereas those in the control group were prescribed 9.32 ± 3.20 (median 9, range 3--21) drugs (*p* \< 0.039 between intervention and control groups).

At admission, at least one DRP could be detected in 86.6% of patients in the intervention group; at discharge this was reduced to 56.0%. DRP and their distribution are presented in [Table 4](#table4-2042098619843365){ref-type="table"}. Out of the variables tested, only GDS \> 5 showed a significant odds ratio with 2.183 (95% confidence interval 1.10--4.34, *p* = 0.026) in the bivariate analysis to experience a DRP at admission. The overall multivariate regression model failed to prove a significant influence of the tested variables on the chance to have a DRP (Nagelkerke's *R*^2^ = 0.037).

###### 

Primary outcome drug-related problems in the control and the intervention groups (full analysis of population).

![](10.1177_2042098619843365-table4)

  Variable                                  Time        Value   Intervention group (*n* = 209)   Control group (*n* = 202)   *p* value (Fisher)           
  ----------------------------------------- ----------- ------- -------------------------------- --------------------------- -------------------- ------- ---------
  PRISCUS PIM (⩾1)                          Admission   No      140                              67.0%                       146                  72.3%   
                                                        Yes     69                               33.0%                       56                   27.7%   0.284
                                            Discharge   No      175                              83.7%                       155                  76.7%   
                                                        Yes     34                               16.3%                       47                   23.3%   0.083
  Drug prescribed without indication (⩾1)   Admission   No      45                               21.5%                       62                   30.7%   
                                                        Yes     164                              78.5%                       140                  69.3%   0.043
                                            Discharge   No      125                              59.8%                       68                   33.7%   
                                                        Yes     84                               40.2%                       134                  66.3%   \<0.001
  Adverse drug reaction (⩾1)                Admission   No      171                              81.8%                       170                  84.2%   
                                                        Yes     38                               18.2%                       32                   15.8%   0.600
                                            Discharge   No      202                              96.7%                       162                  80.2%   
                                                        Yes     7                                3.4%                        40                   19.8%   \<0.001
  Drug--drug interaction (⩾1)               Admission   No      177                              84.7%                       172                  85.2%   
                                                        Yes     32                               15.3%                       30                   14.9%   1
                                            Discharge   No      179                              85.7%                       170                  84.2%   
                                                        Yes     30                               14.4%                       32                   15.8%   0.682
  Combined primary outcome variable         Admission   No      28                               13.4%                       47                   23.3%   
                                                        yes     181                              86.6%                       155                  76.7%   0.011
                                            Discharge   no      92                               44.0%                       48                   23.8%   
                                                        yes     117                              56.0%                       154                  76.2%   \<0.001

The percentages refer to the number of nonmissing values of the row variables within the groups and times (column sum per row variable = 100%).

PIM, potentially inappropriate medication; PRISCUS, .

In the control group, there were slightly less DRPs at admission (76.7%); however, at discharge, there was only a tendency towards an improvement (76.2%). This difference between groups was statistically significant (*p* \< 0.001, see [Table 4](#table4-2042098619843365){ref-type="table"}). Corresponding data for the matched-pairs comparison show a similar difference and can be found in [online Table 5](https://journals.sagepub.com/doi/suppl/10.1177/2042098619843365).

The MAI score in the intervention group could be reduced by 56%, from 56.35 ± 33.84 at admission to 24.92 ± 18.39 at discharge. On the contrary, in the control group, the MAI score remained almost unchanged with 43.21 ± 29.25 at admission and 43.13 ± 30.62 at discharge (*p* \< 0.001). Detailed results of the MAI are presented in [online Table 6](https://journals.sagepub.com/doi/suppl/10.1177/2042098619843365).

A total of 32 ADRs were detected in the control group at admission and *n* = 40 at discharge. The corresponding figures for the intervention group were *n* = 38 and *n* = 7, respectively (*p* \< 0.001). The most frequently ADR-associated drugs were diuretics, antidepressants (citalopram and amitriptyline), analgesics (opioids and nonsteroidal anti-inflammatory drugs) and antithrombotics. The leading presentations of ADR followed a typical geriatric pattern, with electrolyte disorders and exsiccosis, falls, gastrointestinal symptoms and cardiovascular problems (e.g. heart-rhythm disorder, hypotension). More than 80% of the ADRs were classified as type D (NCC MERP), that is, observation or monitoring required. Causality assessment revealed a possible ADR in approximately 80% and in 14%, the ADR was probable. In terms of preventability, 60% of ADRs were classified as preventable, 4% as ameliorable and 36% as nonpreventable.

In the bivariate analyses, women had a significantly higher odds ratio to experience an ADR at baseline with 2.187 (95% confidence interval 1.07--4.46, *p* = 0.032). The multivariate regression model showed no significant influence of the tested variables on the risk of experiencing an ADR at admission (Nagelkerke's *R*^2^ = 0.039).

Pharmaceutical recommendations {#section18-2042098619843365}
------------------------------

The pharmacist detected 1657 pharmaceutical problems as described by Hoth et al.^[@bibr34-2042098619843365]^ in the medication of 209 patients in the intervention group. For 1563 of those problems, pharmaceutical recommendations were written and discussed with the physician. Ninety-four of these problems and recommendations could not be discussed or applied, due to early discharge or patient death.

The largest proportion of recommendations referred to diuretics (9.5%), analgesics (7.6%), antithrombotic drugs (7.5%) and antacid drugs, usually proton-pump inhibitors (7.4%). Almost 25% of recommendations were given for pantoprazole, metoprolol, metamizole (available in Germany), furosemide/torasemide, ramipril and simvastatin. Overall, pharmaceutical recommendations were submitted for 243 different drugs. In all, 37% of pharmacist's recommendation received a high priority, 55% moderate und 8% low priority.

The most frequently stated reasons for a pharmaceutical recommendation were monitoring of side effects and toxicity (28.6%), drug prescribed without indication (18.1%) and DDI (10.4%). Almost half of recommendations (43.8%) fell into the category 'risk to patient', followed by problems with indication/medication (23.2%), pharmaceutical issues (16.8%) and problems regarding effectiveness (15.0%), as depicted in [Figure 2](#fig2-2042098619843365){ref-type="fig"}.

![Pharmacy problem categories according to Hoth et al.^[@bibr34-2042098619843365]^ detected by the pharmacist and discussed with the physician.\
ADE, adverse drug event; ADR, adverse drug reaction; PRISCUS, .](10.1177_2042098619843365-fig2){#fig2-2042098619843365}

The types of pharmaceutical recommendations were classified as shown in [Figure 3](#fig3-2042098619843365){ref-type="fig"}: in 30% of cases monitoring \[laboratory, electrocardiogram (ECG), etc.\] was advised. Second, in 18% of recommendations, drug withdrawal (intermittently or definitely) was stated. In 10%, a dose reduction was suggested and in 8%, replacement by a different drug. [Figure 3](#fig3-2042098619843365){ref-type="fig"} gives an overview of recommendations provided and shows the numbers of recommendations of each type accepted and implemented. [Online Figure 4](https://journals.sagepub.com/doi/suppl/10.1177/2042098619843365) demonstrates an example of a pharmaceutical recommendation. The overall acceptance rate of recommendations was very high, ranging from 96% (change of drug form) to 74% (dose reduction) and 55% (start of drug).

![Type of pharmaceutical recommendation according to Hoth et al.^[@bibr34-2042098619843365]^ and rate of acceptance.](10.1177_2042098619843365-fig3){#fig3-2042098619843365}

Finally, 80% of the recommendations were implemented in the discharge report, 73% without any change and 7% in a modified way; 20% were not implemented.

Discussion {#section19-2042098619843365}
==========

In this pragmatic, controlled trial, we were able to demonstrate a significant influence of pharmacist recommendations on medication quality and safety for geriatric patients. This result is in agreement with other studies, where the number of PIMs or the MAI score had frequently been chosen as primary outcome variables.^[@bibr12-2042098619843365],[@bibr41-2042098619843365][@bibr42-2042098619843365][@bibr43-2042098619843365][@bibr44-2042098619843365][@bibr45-2042098619843365][@bibr46-2042098619843365][@bibr47-2042098619843365]--[@bibr48-2042098619843365]^ We chose a combined-outcome variable, as for these variables: unnecessary drug (without indication) and a major DDI, a substantial risk for ADRs and other adverse outcomes (e.g. falls, hospitalization) has been shown. In addition, we chose the existence of an ADR as one clinically relevant variable.

What concerned us with regard to the prevalence of these risk factors, was the prevalence of PIM according to the PRISCUS list was 30.8% in our cohort, which was markedly higher than expected. Following analyses of German healthcare insurance, a prevalence of 20--25% was assumed.^[@bibr49-2042098619843365],[@bibr50-2042098619843365]^ However, Siebert and colleagues reported a PIM prevalence of 35% at admission to a geriatric department, which was reduced to 29% at discharge.^[@bibr35-2042098619843365]^ In our study, a further reduction to 16.3% was achieved.

DDIs represent a major risk factor for ADRs, and they are frequently detected in observational studies. In our population, 15% of geriatric patients were exposed to a substantial risk, since these DDIs are characterized as 'comedication not recommended' or even 'contraindicated' according to a frequently used DDI software.^[@bibr28-2042098619843365]^ Björkman and colleagues observed DDIs in 46% of elderly patients in six European countries.^[@bibr51-2042098619843365]^ However, a review of 19 studies reported a prevalence of DDI ranging between 2.2% and 70.3% of which between 0.0% and 11.1% were of clinical relevance.^[@bibr52-2042098619843365]^ This discrepancy between DDIs reported by software and clinical outcomes frequently results in an over-alert, with consequent unacceptability of suggested changes.^[@bibr53-2042098619843365][@bibr54-2042098619843365][@bibr55-2042098619843365]--[@bibr56-2042098619843365]^ We thus reported only DDIs with a certain severity and risk for clinical consequences. We cannot rule out that we still over-reported DDIs,^[@bibr57-2042098619843365]^ since the acceptance rate came only to 73%. On the other hand, many DDI-related recommendations suggested monitoring (e.g. an ECG in case of two QT-prolonging drugs) and these ECGs were performed. Consequently, the DDI was still present in the discharge medication. Among other reasons, this may be one explanation for the fact that prevalence of DDIs was the only item of our primary outcome that could not be reduced and was similar between control and intervention groups.

ADRs were observed in 25% of patients at admission. This is in the range of previous studies describing the incidence of ADRs in geriatric patients admitted to hospital.^[@bibr58-2042098619843365][@bibr59-2042098619843365][@bibr60-2042098619843365]--[@bibr61-2042098619843365]^ As reported by others,^[@bibr62-2042098619843365][@bibr63-2042098619843365][@bibr64-2042098619843365]--[@bibr65-2042098619843365]^ electrolyte disorders and exsiccosis induced by diuretics, and falls associated with fall-risk-increasing drugs were the most common ADRs. A thorough medication review should result in a marked reduction of objectively measured and subjectively reported ADRs, as we prove in our intervention group.

The acceptance rate is higher or similar compared with other studies.^[@bibr39-2042098619843365],[@bibr66-2042098619843365][@bibr67-2042098619843365]--[@bibr68-2042098619843365]^ Clinically relevant recommendations and the personal contact to the physicians probably supported the high acceptance rate. Viktil and colleagues found out that proactive communication leads to a higher acceptance rate of pharmaceutical interventions than an indirect method, such as written information.^[@bibr69-2042098619843365]^ Weißenborn and colleagues came to the conclusion that in ambulatory care, a 'successful cooperation between general practitioners and community pharmacist in daily routine care was often characterized by personal contact and long-time relationships'.^[@bibr70-2042098619843365]^

Denneboom analysed the communication between pharmacists and physicians. They compared case conferences with written feedback and also came to the conclusion that with personal contact, the acceptance rate was higher.^[@bibr71-2042098619843365]^ In our study, acceptance rate was high and in most cases, where recommendations were not followed, the physician had additional information, a consultant had to be involved or the issue was already resolved. It should be noted that duration of hospital stay seems to be long; however, this is due to the required minimum of 14 days stay in a geriatric department, including early rehabilitation in accordance with the German system for diagnosis-related groups (DRG).

Most of the recommendations addressed monitoring, deprescribing/stopping of a drug or 'other'. Monitoring comprised checking laboratory values or an ECG, and 'other' includes missing indication (also indication not documented) and missing maximum dose for medication to be given only when needed (e.g. analgesics, neuroleptics). Treatment in a geriatric department can be seen as a chance to safely withhold medications and monitor for potential unwanted effects. The process of deprescribing is currently under debate in many publications,^[@bibr72-2042098619843365],[@bibr73-2042098619843365]^ but was not the focus of the current investigation.

To optimise the intra- and inter-rater reliability of the MAI, a modified MAI was used,^[@bibr29-2042098619843365]^ which additionally considered characteristic features of geriatric medicines. This slightly modified MAI^[@bibr13-2042098619843365],[@bibr29-2042098619843365]^ was the secondary outcome. The MAI is a common tool for measuring medication quality and is used in several studies.^[@bibr43-2042098619843365]^ A significant improvement of the MAI by pharmacist intervention was also investigated by others.^[@bibr67-2042098619843365],[@bibr74-2042098619843365][@bibr75-2042098619843365][@bibr76-2042098619843365]--[@bibr77-2042098619843365]^

There are several limitations of our study. First, the study was only quasi-randomized. However, an allocation bias to one of the two wards was ruled out, since admittance to a certain ward was organized independently from our study. For pragmatic reasons, it was easier to intervene on one ward only, since nurses and physicians on the intervention ward got used to the intervention and we had virtually no contamination to the other ward. In addition, we performed an additional matching approach, where comparable population characteristics were achieved, and statistical analysis revealed identical results for the outcome variables.

Second, we initiated a change in the medication without follow up into ambulatory care. Further studies should examine long-term effects, including a follow up to ambulatory care with clinically relevant endpoints (rehospitalization, quality of life). A randomized prospective trial by Gallagher and colleagues^[@bibr78-2042098619843365]^ including 400 hospitalized geriatric patients showed an increased medication quality using medication review with START/STOPP criteria^[@bibr79-2042098619843365]^ measured by MAI. Their results were sustained for over 6 months after discharge. Due to the experimental nature, we were not able to include patients with cognitive dysfunction who represent a vulnerable population, usually with a high number of drugs prescribed. However, when implemented into routine, their benefit from a pharmaceutical intervention should be at least as large as for the patients studied. Pharmaceutical interventions in nursing homes have been proven successful with regard to MAI and other outcomes describing the quality of the medication, particularly with the use of psychotropic drugs.^[@bibr11-2042098619843365],[@bibr80-2042098619843365]^

This real-life prospective trial showed a high rate of ADRs and other medication-related problems in geriatric patients at hospital admission. The present data confirm the results of recent observations emphasizing the role of pharmaceutical care for hospitalized patients. However, personal contact seems to be relevant to achieve a high acceptance rate of pharmacist's recommendations.
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